Coeptis Therapeutics Holdings Inc Ordinary Shares COEP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if COEP is a good fit for your portfolio.
News
-
Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering
-
Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting
-
Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024
-
Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting
Trading Information
- Previous Close Price
- $0.27
- Day Range
- $0.26–0.27
- 52-Week Range
- $0.23–1.38
- Bid/Ask
- $0.23 / $0.26
- Market Cap
- $9.65 Mil
- Volume/Avg
- 162,837 / 461,274
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 7
- Website
- https://www.coeptistx.com
Valuation
Metric
|
COEP
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.17 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
COEP
|
---|---|
Quick Ratio | 1.54 |
Current Ratio | 1.60 |
Interest Coverage | −57.93 |
Quick Ratio
COEP
Profitability
Metric
|
COEP
|
---|---|
Return on Assets (Normalized) | −236.50% |
Return on Equity (Normalized) | −511.10% |
Return on Invested Capital (Normalized) | −339.94% |
Return on Assets
COEP
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk A/S ADR
NVO
| Nkhgfpbk | Cvsd | $565.6 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Smvxncll | Vtbnq | $127.8 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Zgkdptl | Cdhzt | $118.7 Bil | |||
Moderna Inc
MRNA
| Zmvzgmzl | Hds | $46.8 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Szycskrfm | Thwlhy | $29.7 Bil | |||
argenx SE ADR
ARGX
| Zpqxxlcn | Bbgw | $29.3 Bil | |||
BioNTech SE ADR
BNTX
| Dbvmkdqnp | Pzgr | $20.7 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Svkdjjml | Jwbsvtd | $16.1 Bil | |||
United Therapeutics Corp
UTHR
| Ghdvdbnwm | Vvqnv | $15.0 Bil | |||
Incyte Corp
INCY
| Dbffdfmn | Krpyrlb | $13.5 Bil |